Search bioRxiv⌕ Search

Biology subjects

Rex, A.

Publications and source records attributed to Rex, A..

2 recordsLinked to original sources

Thinking past owl vs owl: The barred owl invasion threatens ecological communities in the western United States

Anthropogenic land use and climate change are facilitating intracontinental species range expansions, leading to novel ecological communities and interactions. Although invasive range-expanders threaten native species, lethal management can be challenged based on the notion that range-expanders are native and therefore less likely to precipitate ecological damage. The anthropogenically-mediated range expansion of barred owls (Strix varia) from eastern to western North America exemplifies this controversy: a recent U.S. Fish and Wildlife Service plan to cull barred owls for the benefit of spotted owls (Strix occidentalis) ignited public outcry and resistance. Here, we assessed barred owls potential invasiveness and broader effects on biodiversity by using molecular methods to characterize the diet of 788 individuals in California, Oregon, and Washington. Barred owls consumed 162 vertebrate and invertebrate prey species, including 29 species with federal- or state-level conservation status. Our findings suggest that barred owls may (1) threaten smaller native predators via intraguild predation and competition for shared prey; and (2) further imperil amphibian communities already threatened by a suite of environmental stressors. We thus contend that barred owls function as an invasive species in their expanded range. The Precautionary Principle suggests that large-scale lethal management is warranted to curb barred owls impacts on not just spotted owls but broader ecological communities in the forests of the Pacific Northwest. More broadly, our study highlights the significant biodiversity loss that could result from range expansions of a generalist predator and provides a roadmap for quantifying putative impacts.

ecology↗

A randomized, controlled, two-center preclinical trial assessing the efficacy of a new benzodiazepine-dihydropyridine hybrid molecule (JM-20) in rodent models of ischemic stroke

JM-20 is a novel multifunctional benzodiazepine molecule with potent neuroprotective effects in rat focal cerebral ischemia. To confirm previous results obtained in single laboratories with small sample sizes, and to provide a robust preclinical evidence base for potential clinical development in stroke, we have performed a two-center preclinical trial with sufficiently large group sizes to detect relevant effects, minimizing biases in experimental design as much as possible (randomization, blinding, predefined in- and exclusion criteria) and increasing external and construct validities by performing experimental focal cerebral ischemia by different surgeons in two different laboratories on two continents, including two species (480 mice and 55 rats), different suppliers, young, young adult, and mature adult animals (range 2 -16 months) as well as comorbid animals (diabetes). While JM-20 improved functional outcomes after middle cerebral artery occlusion in young adult mice at day 7 and appeared to reduce mortality (not statistically significant), it had no effect in mature adult or comorbid (STZ-induced diabetes) mice. Effect sizes, where statistically significant, were modest, and much lower than those reported in the previous studies. Meta-analysis of all individual mouse data did not reveal statistically significant different functional outcomes or mortalities between vehicle- and JM-20-treated animals, although neuroscores and survival were slightly better in JM-20-treated animals. In the less severe model of permanent cortical focal cerebral ischemia in rats, JM-20 significantly reduced brain infarction. We conclude that we were able to confirm the neuroprotective potential of JM-20. However, effect sizes were substantially lower as previously described in small, monocentric trials. Further study is needed to determine whether JM-20 could be effective in less severe cases of focal cerebral ischemia or when used in combination with thrombolysis.

pharmacology and toxicology↗